Affiliation:
1. Division of Vector-Borne Diseases, Centers for Diseases Control and Prevention, Fort Collins, Colorado, USA
Abstract
SUMMARY
Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology
Reference141 articles.
1. An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953
2. Jupp PG, McIntosh BM. 1988. Chikungunya virus disease, p 137–157. In Monath TP (ed), The arbovirus: epidemiology and ecology, vol II. CRC Press, Boca Raton, FL.
3. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. IV. Epidemiologic studies in the Bangkok metropolitan area;Halstead SB;Am J Trop Med Hyg,1969
4. Concurrent Isolation from Patient of Two Arboviruses, Chikungunya and Dengue Type 2
5. Recent epidemics caused by chikungunya virus in India, 1963-1965;Rao TR;Sci Cult,1966
Cited by
107 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献